# THRM earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/THRM) · [Earnings tab](https://www.lopjlb.com/stock/THRM?tab=earnings)

Updated: 2026-10-23T08:29:53

Quarters analyzed: 8

## Cross-quarter narrative

Across 8 calls for THRM, management tone moved from +0.60 (2024 Q4) to +0.60 (2026 Q3). Latest guidance stance: maintained. Latest desk line: Gentherm reports diversified growth, new product launches and integration progress, while noting inflation‑driven margin pressure and modest guidance updates.

## Latest CallCard · Q3

Gentherm reports diversified growth, new product launches and integration progress, while noting inflation‑driven margin pressure and modest guidance updates.

**Guidance:** maintained — full-year revenue $1.875B, EBITDA $220M, free cash flow $110M unchanged from prior guidance

**Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3

prepared remarks emphasized diversified portfolio, growth opportunities, confidence in synergy and margin expansion

### Demand visibility

strong visibility to growth from automotive, power generation and commercial vehicle opportunities

legacy Gentherm automotive launch activity and Modine power generation, commercial vehicles, China domestic sales strength

### Margins / costs

margin pressure from material inflation, freight and FX, partially offset by higher capacity utilization and cost‑of‑nonconformance reductions

inflation and freight cost recovery lag, plant restructuring, 80/20 efficiency drive

### Capital allocation

active share repurchase, modest $55M capex, focus on cost synergies and footprint consolidation

$340M buyback authorization, $60M repurchased Q4, $55M capex, $25M cost synergies target

### Milestones

- **Puls.A massage system launch** [delivered]: first ever automotive massage system launched in Q3
- **ThermAffyx patient safety system** [delivered]: FDA cleared and launched with initial sales in Q3
- **Acquisition of Innovative Medical Equipment** [delivered]: completed, expanding patient thermal management portfolio
- **India air moving devices award** [new]: ~$25M lifetime revenue, shipments start Q4 2027
- **Home and office market pipeline** [on_track]: visibility to $30M annualized revenue, pipeline supports $100M target by 2028
- **Power generation backlog** [on_track]: building backlog for diesel generation and data center applications
- **European footprint consolidation (Czech Republic)** [on_track]: expected completion Q4 2026
- **North America Mexico facility consolidation** [delivered]: largely completed

### Fears / risks

- **Inflation**: material and freight cost inflation eroding gross margins
- **FX volatility**: Mexican peso movements impacting earnings
- **Integration risk**: early stage Modine integration may delay synergies
- **Revenue synergy timing**: major synergy benefits not expected until 2028‑2030
- **Automotive market flatness**: light vehicle production down, automotive demand flat
- **Share price dislocation**: stock price decline affecting buyback timing
- **Regulatory**: FDA clearance required for medical product launches
- **Operational restructuring**: footprint consolidation and plant restructuring may cause temporary disruptions

### Key quotes

> “We have emerged as a fundamentally different company, a global leader in innovative thermal and precision flow management technologies with a more diversified portfolio, incremental secular growth drivers, enhanced margin expansion”

> “We now expect the midpoint guidance for the full year to be as follows: revenue of $1.875 billion, adjusted EBITDA of $220 million and free cash flow of approximately $110 million with assumed CapEx of $55 million.”

> “Gross margins were down year-over-year, not surprising given all of the inflation and higher freight costs.” — Nathan Jones

> “The $28 million EBITDA, $275 million revenue, it seems like around 10% EBITDA margins, which is a little lower than at the time of the acquisition, where I think it was tracking at 11%.” — Rajat Gupta

> “Power generation side, a lot of what they're doing is supporting diesel generation, which is after meter power. A lot of that is going into the data center.”

## Quarter one-liners

- **2026 Q3:** Gentherm reports diversified growth, new product launches and integration progress, while noting inflation‑driven margin pressure and modest guidance updates.
- **2026 Q2:** Gentherm raised FY2026 guidance on strong automotive awards and new market wins, while advancing its Modine merger, medical FDA clearance and IME acquisition.
- **2026 Q1:** Gentherm Q1 2026 showed record automotive revenue and strong execution, but faces macro uncertainty, $20M cost pressure and margin headwinds while progressing its Modine merger and new market launches.
- **2025 Q4:** Gentherm reported modest revenue growth, margin pressure from material costs, and highlighted its Modine merger, adjacent market expansion and medical product launch while guiding 2026 revenue $1.5‑$1.6B and EBITDA $175‑$195M.
- **2025 Q3:** Gentherm posts record Q3 revenue of $387M, raises full-year revenue guidance midpoint, narrows EBITDA margin range; highlights $745M new business awards including Mercedes conquest win, $300M adjacent market funnel, and footprint realignment on track for 2026 completion.
- **2025 Q2:** —
- **2025 Q1:** —
- **2024 Q4:** Gentherm's new CEO highlighted strong product awards, a 30% footprint reduction plan and growth prospects, while analysts probed award backlog, China mix shift and capital allocation, indicating moderate optimism.

## Theme arcs

- **Management tone** (stable): Δ mgmt=+0.00

## Fear persistence

- **demand slowdown** [resolved]: 2024 Q4
- **execution risk** [resolved]: 2024 Q4
- **award backlog timing** [resolved]: 2024 Q4
- **geopolitical/tariff risk** [resolved]: 2024 Q4
- **currency risk** [resolved]: 2024 Q4
- **competitive pressure** [resolved]: 2024 Q4
- **capital allocation risk** [resolved]: 2024 Q4
- **supply chain constraints** [resolved]: 2024 Q4
- **supply chain disruption** [resolved]: 2025 Q3
- **margin pressure** [recurring]: 2025 Q3, 2026 Q1

## Guidance path

2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:raised → 2025 Q4:maintained → 2026 Q1:maintained → 2026 Q2:raised → 2026 Q3:maintained

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/THRM`